Clinical trials for Skin cancer (melanoma)

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Skin cancer (melanoma). For all clinical trials, go to clinical trials search

This list shows clinical trials for Skin cancer (melanoma)

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Skin cancer (melanoma)
Title Recruitment status Location
A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIB PLUS GDC-0973 (COBIMETINIB) IN PREVIOUSLY UNTREATED BRAFV600-MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA Recruiting United Kingdom
A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma Recruiting United Kingdom
A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma Recruiting United Kingdom
COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection Recruiting United Kingdom
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Recruiting United Kingdom
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody Recruiting United Kingdom
A Randomized, Double-Blind, Phase III Trial of STA-4783 in Combination with Paclitaxel versus Paclitaxel Alone for Treatment of Chemotherapy-Naïve Subjects with Stage IV Metastatic Melanoma Not Recruiting United Kingdom
A Multi-Center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients with Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg of Ipilimumab (MDX-010) vs. Dacarbazine With Placebo. Revised Protocol 03, incorporating Administrative Letter 01, Administrative Letter 02, Amendment 02, and Amendment 06 Not Recruiting United Kingdom
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Phase III Study in Previously untreated Patients with Unresectable Stage IIIC or Stage IV Melanoma with V600E BRAF mutation Receiving Vemurafenib (RO5185426) or Dacarbazine. - BRIM 3 Not Recruiting United Kingdom
A study conducted in many hospitals, carried out in two groups of patients with advanced skin cancer who know that they are receiving the study medication and have previously received treatment for their advanced skin cancer and the disease has progressed since that treatment Not Recruiting United Kingdom

Page last reviewed: 14/12/2010

Next review due: 14/12/2012